AnaptysBio Inc

ANAB remains in Stage 4 Decline with a decisive Support Failure and down-sloping EMAs confirming continued medium-term bearish bias; price sits below key moving averages with a recent rejection at the 9/20 EMA and 50 SMA zone, supporting immediate sell-side participation. Sell now into rallies.

• ↑$100M stock repurchase may boost share price amid undervaluation
• ↑Revenue of $25.6M topped expectations despite $1.84 EPS loss
• ↓EPS loss of $1.84 underscores weak profitability and cash burn